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Available online 29 January 2016Human immunodeﬁciency virus (HIV) infection progressively de-
stroys CD4+ mononuclear cells leading to profound cellular immune
Independently, three studies reported that theHIV-infected subjects haddeﬁciency that manifests as life threatening opportunistic infections
and malignancies, i.e., the acquired immune deﬁciency syndrome
(AIDS). The gut mucosa-associated lymphoid tissue (MALT, e.g., Peyer's
patches) is a major locus of CD4+ cells. HIV's asymptomatic and insid-
ious destruction of these cells compromises the integrity of the gut mu-
cosa, allowing translocation (leakage) of microbes and other luminal
contents into the circulation (Brenchley et al., 2004). Microbial translo-
cation induces subtle but sustained andwidespread immune activation,
which is a major contributor to HIV's pathogenesis (Brenchley et al.,
2006).
Given these effects of HIV on the gut mucosa, it is not surprising that
several groups have reported alterations of the gut microbial population
(themicrobiota) in peoplewithHIV, including those inwhomHIV iswell
controlled with antiretroviral therapy (ART) (Lozupone et al., 2014;
Nowak et al., 2015). These studies comprised heterogeneous or poorly
deﬁned populations, used various methods, and have been very
small — collectively fewer than 100 HIV-infected subjects including
those with early HIV, HIV on ART, chronic HIV viremia without ART,
and “elite controllers” (non-viremic without ART). In one recent report
(Nowak et al., 2015), species-level diversity (termed richness or “alpha
diversity”) in feces in 28 HIV viremic patients was signiﬁcantly lower
than in 9 controls; alpha diversity correlated positively with CD4+ cell
counts and inversely with plasma markers of microbial translocation
and monocyte activation. After ART initiation in these subjects, fecal
alpha diversity continued to decrease (Nowak et al., 2015), which cor-
roborates ﬁndings from others (Lozupone et al., 2014). In contrast, a
more recent and comprehensive study (Mutlu et al., 2014) reported
that fecal alpha diversity did not differ between 21HIV-infected subjects
and 22 demographically similar, HIV-uninfected controls, although their
HIV subjects did have signiﬁcantly lower alpha diversity in multipleDOI of original article: http://dx.doi.org/10.1016/j.ebiom.2016.01.032.
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clusion by Lozupone et al. (2014) that mucosal alpha diversity does not
differ consistently with untreated HIV.
Considering the composition of the microbial community (termed
“beta diversity” or, colloquially, “who's there”), the review by Lozupone
et al. (2014) noted a shift in a major phylum of the gut microbiota,
Bacteroidetes. Compared to various uninfected controls, colon mucosal
biopsies and also feces from HIV-infected subjects, irrespective of ART,
had lower abundanceof Bacteroides andhigher abundance of Prevotella.
increased abundance of Proteobacteria, including several potential path-
ogens, in biopsies but not in feces [reviewed in (Lozupone et al., 2014)].
Higher abundance of mucosal-adherent Proteobacteria supports the hy-
pothesis that an alteredmicrobiota (“dysbiosis”) contributes to a vicious
cycle of inﬂammation, gut permeability, microbial translocation, and
progressive immunedeﬁciency through depletion of CD4+mononucle-
ar cells (Vyboh et al., 2015).
In this issue of EBioMedicine, Noguera-Julian et al. (2016) push
this topic in a new direction in their study of men who have sex with
men (MSM) and others in Barcelona and Stockholm. Their participants,
129 HIV-positives (60% MSM) and 27 HIV-negatives (85% MSM) in
Barcelona, and 77 HIV-positives (25% MSM) and 7 HIV-negatives
(none MSM) in Stockholm, provided one sample of feces. Microbiota
proﬁles in the fecal DNA were generated by amplifying and next-
generation sequencing 16S rRNA genes. The sequences were assigned
to prokaryotic taxa and processed to generate diversity metrics.
Like some previous studies (Nowak et al., 2015), fecal microbiota rich-
ness was lower in most HIV subjects. Unlike some previous studies,
HIV was not associated with higher Prevotella-related and lower
Bacteroides-related taxa (Lozupone et al., 2014).
The novelty of the current report is the focus onHIV risk group, specif-
ically MSM (Noguera-Julian et al., 2016), whereas sexual orientation and
other HIV risk categories were largely ignored in the previous reports.
Noguera-Julian and colleagues reported that Prevotella taxa predominat-
ed in MSM, whereas Bacteroides taxa predominated in non-MSM. Com-
pared to non-MSM, MSM also had higher richness partially attributable
to their lower HIV prevalence (60% vs 85% in Barcelona, 62% vs 100% in
Stockholm). Given that HIV-negative MSM are largely healthy, the differ-
ences noted by sexual orientation stretch the concept of “dysbiosis.”
The possibility that these new associations reﬂect confounding
should be considered, particularly with the heterogeneity of the study
populations. The authors looked for but could not ascribe the gutmicro-
biota alterations to MSM-related differences in diet or particular co-ense (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Chlamydia trachomatis). However, current or prior enteric parasites
with relatively high prevalence in MSM (e.g., amoebiasis (Hung et al.,
2012)) were not considered. Antibiotic use could be a major con-
founder. Most subjects were excluded if they had received antibiotics
during the previous 3 months, but cumulative or prior antibiotic
exposure (within 6 months noted for 24% of HIV-positive, 15% of HIV-
negative, 20% of MSM, and 27% of non-MSM in Barcelona) could have
contributed.
In our study of 76 MSM from a well deﬁned population, we found
that the analmicrobiota (which closely resembled the fecal microbiota)
had altered composition and reduced richness with uncontrolled,
advanced HIV infection (Yu et al., 2014). Importantly, these alterations
in the microbial population were partially attributable to antibiotic use
but not to T-cell subset levels, smoking, or sexual practices (e.g., anal in-
tercourse, anilingus) (Yu et al., 2014).
Validation, and indeed formal testing of the hypothesis posed by
Noguera-Julian and colleagues, that the gut microbiota differs by sexual
orientation, will be needed. Such a study would be challenging, given
the need to avoid or minimize confounding by demographics, diet,
physical activity, HIV and other infections, and medications particularly
antibiotics. In the meantime, all studies of HIV-microbiota relationships
should carefully investigate possible confounding or effect modiﬁcation
by sexual orientation, injection drug use, and demographics.
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